Movement Alert｜HANSOH PHARMA rises 3.02% in Regular Trading, innovation drug strength and ADC outbound theme stay in focus

Market Focus10-28

On October 28, HANSOH PHARMA rose 3.02% intraday, trading at HK$32.8, with turnover of HK$214 million.

The move aligned with a broader rally in innovation drug names, as market attention remained on China innovative drug outbound licensing opportunities, especially in ADC and bispecific antibody segments.

Recent company-specific context remains centered on HANSOH PHARMA's strategic ADC collaboration and licensing agreement with Roche. The deal covers two preclinical ADC programs and additional ADC projects based on HANSOH PHARMA's proprietary platform. Under the agreement, the company will receive a US$400 million upfront payment and a further US$110 million on the first anniversary, while remaining eligible for more than US$15 billion in potential milestone payments plus tiered royalties. Several brokers said the transaction validates the company’s ADC platform competitiveness and improves visibility on overseas value realization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment